Grace Therapeutics (GRCE) Total Current Liabilities (2017 - 2026)

Grace Therapeutics has disclosed Total Current Liabilities across 10 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 46.0% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $1.2 million (down 46.0% YoY), while the FY2026 annual figure was $2.1 million, up 11.19% from the prior year.
• Total Current Liabilities came in at $1.2 million for Q2 2026 at Grace Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $3.8 million in Q3 2022 to a low of $1.2 million in Q3 2025.
• Average Total Current Liabilities over 5 years is $2.3 million, with a median of $2.1 million recorded in 2024.
• Year-over-year, Total Current Liabilities surged 106.46% in 2022 and sank 63.29% in 2023.
• Over 5 years, Total Current Liabilities stood at $3.4 million in 2022, then sank by 48.44% to $1.8 million in 2023, then advanced by 11.36% to $2.0 million in 2024, then sank by 34.86% to $1.3 million in 2025, then slipped by 2.65% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $1.2 million in Q2 2026, $2.1 million in Q1 2026, and $1.3 million in Q4 2025.